Eisai releases results of rufinamide study

Eisai Inc. has released the final results of its Phase 3 rufinamide study, an open-label, two-year investigation.
The results were presented at the 2016 Annual Meeting of the American Epilepsy Society held in Houston this week.
Rufinamide, which is being marketed as BANZEL, was approved for the treatment of seizures that are linked with Lennox-Gastaut Syndrome (LGS) in adults and pediatric patients who are at least 1 year old.
"LGS is a rare, complex and difficult to treat condition," Eisai Executive Vice President and co-author of the study Dr. Andrew Satlin said. "We are pleased to provide these additional data on rufinamide's safety and tolerability, and on cognitive development and behavior. Eisai remains committed to continued research and fulfilling the needs of this underserved population."
The Phase 3 study assessed safety, tolerability and cognitive data of patients who were administered the therapy that included rufinamide and achieved comparable safety and tolerability profiles, cognitive development and behavior compared to patients who were the recipient of antiepileptic drug treatment chosen by the investigators.